Severe Acute Respiratory Syndrome (SARS) – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Severe Acute Respiratory Syndrome (SARS) – Pipeline Review, H2 2019’, provides an overview of the Severe Acute Respiratory Syndrome (SARS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS)

– The report reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Severe Acute Respiratory Syndrome (SARS) therapeutics and enlists all their major and minor projects

– The report assesses Severe Acute Respiratory Syndrome (SARS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abhelix LLC

Atriva Therapeutics GmbH

Autoimmune Technologies LLC

Biotron Ltd

CEL-SCI Corp

Fab’entech SA

GeneCure LLC

Gilead Sciences Inc

Novavax Inc

Oncovir Inc

Phelix Therapeutics LLC

Sagimet Biosciences

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Severe Acute Respiratory Syndrome (SARS) ”“ Overview

Severe Acute Respiratory Syndrome (SARS) ”“ Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Severe Acute Respiratory Syndrome (SARS) ”“ Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Severe Acute Respiratory Syndrome (SARS) ”“ Companies Involved in Therapeutics Development

Abhelix LLC

Atriva Therapeutics GmbH

Autoimmune Technologies LLC

Biotron Ltd

CEL-SCI Corp

Fab’entech SA

GeneCure LLC

Gilead Sciences Inc

Novavax Inc

Oncovir Inc

Phelix Therapeutics LLC

Sagimet Biosciences

Severe Acute Respiratory Syndrome (SARS) ”“ Drug Profiles

ATR-006 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEL-1000 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSW-1 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit Cathepsin L for Coronaviridae Infections ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FDX-000 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LB-2 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ML-188 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody for SARS Virus Infections ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Poly-ICLC ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remdesivir ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SARS (virus like particle) vaccine ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

severe acute respiratory syndrome vaccine ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Coronavirus E Protein for Severe Acute Respiratory Syndrome ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSYA-10001 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TVB-3567 ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Severe Acute Respiratory Syndrome ”“ Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Severe Acute Respiratory Syndrome (SARS) ”“ Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Severe Acute Respiratory Syndrome (SARS) ”“ Pipeline by Abhelix LLC, H2 2019

Severe Acute Respiratory Syndrome (SARS) ”“ Pipeline by Atriva Therapeutics GmbH, H2 2019

Severe Acute Respiratory Syndrome (SARS) ”“ Pipeline by Autoimmune Technologies LLC, H2 2019

Severe Acute Respiratory Syndrome (SARS) ”“ Pipeline by Biotron Ltd, H2 2019

Severe Acute Respiratory Syndrome (SARS) ”“ Pipeline by CEL-SCI Corp, H2 2019

Severe Acute Respiratory Syndrome (SARS) ”“ Pipeline by Fab’entech SA, H2 2019

Severe Acute Respiratory Syndrome (SARS) ”“ Pipeline by GeneCure LLC, H2 2019

Severe Acute Respiratory Syndrome (SARS) ”“ Pipeline by Gilead Sciences Inc, H2 2019

Severe Acute Respiratory Syndrome (SARS) ”“ Pipeline by Novavax Inc, H2 2019

Severe Acute Respiratory Syndrome (SARS) ”“ Pipeline by Oncovir Inc, H2 2019

Severe Acute Respiratory Syndrome (SARS) ”“ Pipeline by Phelix Therapeutics LLC, H2 2019

Severe Acute Respiratory Syndrome (SARS) ”“ Pipeline by Sagimet Biosciences, H2 2019

Severe Acute Respiratory Syndrome (SARS) ”“ Dormant Projects, H2 2019

Severe Acute Respiratory Syndrome (SARS) ”“ Dormant Projects, H2 2019 (Contd..1), H2 2019

List of Figures

List of Figures

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports